APA (7th ed.) Citation

Du, K., Shen, H., Pan, B., Luthuli, S., Wang, L., Liang, J., . . . Xu, W. (2024). Prognostic value of POD18 combined with improved IELSG in primary central nervous system lymphoma. Clinical and Translational Oncology, 26(3), 720-731. https://doi.org/10.1007/s12094-023-03292-5

Chicago Style (17th ed.) Citation

Du, Kai-Xin, et al. "Prognostic Value of POD18 Combined with Improved IELSG in Primary Central Nervous System Lymphoma." Clinical and Translational Oncology 26, no. 3 (2024): 720-731. https://doi.org/10.1007/s12094-023-03292-5.

MLA (9th ed.) Citation

Du, Kai-Xin, et al. "Prognostic Value of POD18 Combined with Improved IELSG in Primary Central Nervous System Lymphoma." Clinical and Translational Oncology, vol. 26, no. 3, 2024, pp. 720-731, https://doi.org/10.1007/s12094-023-03292-5.